Pathogenic Infections

  • Sepsis: the EMCD can save millions of patients worldwide with its efficient removal of all pathogens in the bloodstream, preventing any sort of inflammation
  • HIV/AIDS: the EMCD will be able to bind to the HIV virus, reducing proliferation and progression to AIDS.
    It also helps HIV/AIDS patients to survive pathogenic attacks even with their weak immune system
  • Immunodeficiency Disorders: people born with immunodeficiency disorders will have an easy, efficient, and quick process to rid their blood of pathogens
  • Organ Transplants: the EMCD allows for the immunosuppressant to do its job without placing the patient at extreme risk
  • Other Bacterial and Viral Diseases: the EMCD quickly and completely removes the pathogens from the body


  • no need to identify the pathogen before treatment as MBLs can bind to a wide variety of pathogens and toxins
  • the EMCD completely eliminates the bacteria unlike antibiotic treatments, removing any debris to help reduce the over-excited inflammatory response
  • the EMCD does not contribute to antibiotic resistance

Sepsis is very costly


  • Sepsis is the most expensive medical condition. Hospitals in the United States spend over $20,000,000 annually to treat 1,600,000 million sepsis patients
  • Lifetime Antiretroviral Therapy (ART) for HIV/AIDS costs around $367,134 per person
  • The EMCD is a cheap solution to both, as the genetically modified MBLs comprise the majority of its cost. However, the MBLs, like all other aspects of the EMCD, can easily be mass produced.


  • Genetically engineering MBLs could be costly and difficult to manufacture
  • May harm the Antiretroviral Therapy (ART) and antibiotic industries
  • Little to no environmental footprint after manufacturing

Copyright © EMCD 2015